Gilead Sciences’ quarterly adjusted earnings came in at $1.87 per share for the quarter ended June, surpassing Zacks Consensus Estimate of $1.76 per share. It was $1.11 per share in the year-ago quarter.
The biopharma company has exceeded consensus EPS estimates four times over the last four quarters.
Gilead’s revenues were $6.22 billion, beating the Zacks Consensus Estimate by 1.14%. Sales were $5.14 billion in the year-ago period. The company beat consensus revenue estimates three times over the last four quarters.